{"id":30154,"date":"2025-11-17T10:39:16","date_gmt":"2025-11-17T09:39:16","guid":{"rendered":"https:\/\/ichp.lukasiewicz.gov.pl\/api-syntesis\/"},"modified":"2026-03-09T10:58:52","modified_gmt":"2026-03-09T09:58:52","slug":"api-syntesis","status":"publish","type":"page","link":"https:\/\/ichp.lukasiewicz.gov.pl\/en\/api-syntesis\/","title":{"rendered":"API syntesis"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Department of Pharmaceutical Products<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Development of Active Pharmaceutical Ingredient (API) manufacturing technology<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

– Development of technologies for the production of active substances on a mini-synthetic and semi-technical scale<\/h3>

– Scaling up with validation of ongoing processes<\/h3>

– Organic synthesis of GMP and non-GMP<\/h3>

– Conducting various chemical processes (synthesis, catalytic reduction, oxidation, condensation, cyclisation) and physicochemical processes (jet micronisation, crystallisation, large-scale liquid chromatography, fractional distillation) in qualified equipment and technological installations.<\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

API for commercialisation<\/p>
Substance<\/strong><\/td>Field of activity<\/strong><\/td><\/tr>
1. Bimatoprost<\/td>Analog prostaglandyny F2\u03b1 stosowany w leczeniu jaskry i wysokiego ci\u015bnienia w ga\u0142ce ocznej<\/td><\/tr>
2. Bosentan<\/td>A dual endothelin receptor antagonist (ERA) with affinity for ETA and ETB receptors. Reduces pulmonary and systemic vascular resistance; hypertension. <\/td><\/tr>
3. Brinzolamide<\/td>Glaucoma, carbonic anhydrase inhibitor<\/td><\/tr>
4. Exemestane<\/td>Irreversible steroidal aromatase inhibitor, breast cancer<\/td><\/tr>
5. Fingolimod<\/td>Multiple sclerosis<\/td><\/tr>
6. Lapatinib<\/td>Inhibitor of EGFR (ErbB1) and ErbB2 (HER2) tyrosine kinase; lung and breast cancer, breast cancer with overexpression of the HER2 (ErbB2) receptor<\/td><\/tr>
7. Nepafenac<\/td>Precursor of non-steroidal anti-inflammatory drugs; cataracts: prevention and treatment of pain and inflammation after surgery, reduction of the risk of postoperative macular oedema<\/td><\/tr>
8. Olopatadine<\/td>Antihistamine and anti-inflammatory drug<\/td><\/tr>
9. Oseltamivir<\/td>Antiviral medicine indicated for the treatment of influenza<\/td><\/tr>
10. Pemetrexed<\/td>Folic acid antagonist, treatment of non-small cell lung cancer<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Analytical patterns<\/p>
  • Alfacalcidol<\/li>
  • Alfacalcidol<\/li>
  • Amitraz<\/li>
  • Anastrozole<\/li>
  • Bimatoprost<\/li>
  • Calcifediol<\/li>
  • Calcipotriol<\/li><\/ul><\/td>
  • Calcitriol<\/li>
  • Capecitabine<\/li>
  • Carvedilol<\/li>
  • Duloxetine hydrochloride<\/li>
  • Imatinib<\/li>
  • Lacidipine<\/li>
  • Latanoprost<\/li><\/ul><\/td>